Literature DB >> 1356634

Stimulation of IFN-gamma, TNF-alpha, and TNF-beta secretion in IL-2-activated T cells: costimulatory roles for LFA-1, LFA-2, CD44, and CD45 molecules.

A S Chong1, I A Boussy, L H Graf, P Scuderi.   

Abstract

Lymphokine-activated killer (LAK) cells are peripheral blood lymphocytes (PBLs) that possess the ability to kill target cells in a non-major histocompatibility complex (MHC)-restricted manner. Both NK and T cells can be stimulated with interleukin-2 (IL-2) to become LAK cells. We previously reported that the interaction of LAK cells with tumor cells also induces the secretion of interferon-gamma (IFN-gamma). The NK subset of LAK (LAK-NK) cells is stimulated by tumor cells to secrete IFN-gamma in a non-MHC-restricted manner while the T cell subset of LAK (LAK-T) cells is stimulated to secrete IFN-gamma upon cross-linking of the T cell receptor (TCR)-CD3 complex. We here report that LAK-T cells stimulated with anti-CD3 mAbs and tumor cells secrete two additional cytokines, tumor necrosis factor-alpha (TNF-alpha) and TNF-beta/lymphotoxin (TNF-beta). In addition, we demonstrate that at least four other structurally unrelated molecules, in addition to the TCR-CD3 complex, on LAK-T cells participate in the stimulation of IFN-gamma, TNF-alpha, and TNF-beta production. These molecules are the lymphocyte function associated antigen-1 (LFA-1), lymphocyte function associated antigen-2 (LFA-2), CD44, and CD45. LFA-1 is an integrin, LFA-2 is a member of the immunoglobulin supergene family, CD44 is homologous to the cartilage link proteins, and CD45 is a tyrosine phosphatase. Ligands to three of these molecules have been identified; ICAM-1, LFA-3, and hyaluronic acid binding to LFA-1, LFA-2, and CD44, respectively. LFA-1, LFA-2, and CD44 are reported to function both as adhesion molecules and as costimulators in resting T cells. Our data suggest that these three molecules enhance IFN-gamma, TNF-alpha, and TNF-beta production by augmenting LAK-T cell to tumor cell adhesion and also by functioning as costimulators.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1356634     DOI: 10.1016/0008-8749(92)90226-f

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  7 in total

1.  Production of tumour necrosis factors by human T cells stimulated by a superantigen, toxic shock syndrome toxin-1.

Authors:  H Akatsuka; K Imanishi; K Inada; H Yamashita; M Yoshida; T Uchiyama
Journal:  Clin Exp Immunol       Date:  1994-06       Impact factor: 4.330

2.  Expression of CD44 on rheumatoid synovial fluid lymphocytes.

Authors:  D Kelleher; A Murphy; N Hall; M B Omary; G Kearns; A Long; E B Casey
Journal:  Ann Rheum Dis       Date:  1995-07       Impact factor: 19.103

Review 3.  CD44: physiological expression of distinct isoforms as evidence for organ-specific metastasis formation.

Authors:  M Zöller
Journal:  J Mol Med (Berl)       Date:  1995-09       Impact factor: 4.599

4.  Role of membrane-associated lymphotoxin (mLT) in the killing activity of lymphokine-activated killer (LAK) cells towards various tumour cell lines.

Authors:  A Horiuchi; Y Abe; M Miyake; K Kimura; Y Hitsumoto; N Takeuchi; S Kimura
Journal:  Clin Exp Immunol       Date:  1994-04       Impact factor: 4.330

5.  ICAM-1 and LFA-3 enhance the ability of anti-CD3 mAb to stimulate interferon gamma production in interleukin-2-activated T cells.

Authors:  A S Chong; X L Jiang; P Scuderi; M Lamas; L H Graf
Journal:  Cancer Immunol Immunother       Date:  1994-08       Impact factor: 6.968

6.  gamma Interferon gene expression and release in human lymphocytes directly activated by Cryptococcus neoformans and Candida albicans.

Authors:  S M Levitz; E A North
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

7.  Analysis of cytotoxic activity of the CD4+ T lymphocytes generated by local immunotherapy.

Authors:  Y Katsumoto; T Monden; T Takeda; A Haba; Y Ito; E Wakasugi; T Wakasugi; M Sekimoto; T Kobayashi; H Shiozaki; T Shimano; M Monden
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.